KURA Kura Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KURA

Price (delayed)

$8.805

Market cap

$781.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

$766.85M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 21

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable ...

Highlights
The gross profit has grown by 6% from the previous quarter and by 4.9% YoY
Kura Oncology's revenue has increased by 6% from the previous quarter and by 5% YoY
The equity has plunged by 70% YoY and by 38% from the previous quarter
Kura Oncology's net income has plunged by 62% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kuraoncology.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KURA

KURA stock price

How has the Kura Oncology stock price performed over time
Intraday
1.73%
1 week
-11.69%
1 month
-4.81%
1 year
36.51%
YTD
-15.26%
QTD
8.3%

Financial performance

How have Kura Oncology's revenue and profit performed over time
Revenue
$71.64M
Gross profit
$71.32M
Operating income
-$317.75M
Net income
-$294.57M
Gross margin
99.6%
Net margin
-411.2%
Kura Oncology's net income has plunged by 62% YoY and by 6% from the previous quarter
The company's operating income has shrunk by 56% YoY and by 4.6% QoQ
The net margin has dropped by 54% year-on-year
KURA's operating margin is down by 48% year-on-year

Price vs fundamentals

How does KURA's price correlate with its fundamentals

Growth

What is Kura Oncology's growth rate over time

Valuation

What is Kura Oncology stock price valuation
P/E
N/A
P/B
7.21
P/S
10.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.7
The company's EPS has shrunk by 60% YoY and by 5% QoQ
The stock's P/B is 163% above its 5-year quarterly average of 2.7 and 69% above its last 4 quarters average of 4.2
The equity has plunged by 70% YoY and by 38% from the previous quarter
The price to sales (P/S) is 15% higher than the last 4 quarters average of 9.3
Kura Oncology's revenue has increased by 6% from the previous quarter and by 5% YoY

Efficiency

How efficient is Kura Oncology business performance
The return on invested capital has dropped by 62% year-on-year and by 11% since the previous quarter
The company's return on sales has shrunk by 56% YoY
The ROA has contracted by 49% YoY and by 9% from the previous quarter
The return on equity has declined by 38% since the previous quarter

Dividends

What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KURA.

Financial health

How did Kura Oncology financials performed over time
KURA's total assets is 20% greater than its total liabilities
KURA's total liabilities is up by 44% year-on-year but it is down by 3.5% since the previous quarter
The quick ratio has contracted by 26% YoY
The debt is 78% smaller than the equity
The debt to equity has surged by 83% since the previous quarter
The equity has plunged by 70% YoY and by 38% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.